Verona Pharma (VRNA) announced its shareholders have approved the proposal for Merck (MRK) to acquire the company for $107 per ADS, for a total transaction value of approximately $10B. The transaction is being implemented by a scheme of arrangement under English law and remains subject to the sanction of the High Court of Justice of England and Wales. The court hearing to sanction the scheme has been scheduled for October 6.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA: